Rosenberg, Jonathan E <br/><br/>
Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?  [electronic resource] 

 -  Clinical prostate cancer  Sep 2004 
 - 122-4 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1540-0352 
<br/><br/><label>Standard No.: </label>10.3816/cgc.2004.n.022  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Androgen Antagonists--adverse effects<br/>Clinical Trials, Phase III as Topic<br/>Docetaxel<br/>Drug Resistance, Neoplasm<br/>Humans<br/>Male<br/>Middle Aged<br/>Mitoxantrone--administration & dosage<br/>Neoadjuvant Therapy<br/>Neoplasm Staging<br/>Prognosis<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms--drug therapy<br/>Randomized Controlled Trials as Topic<br/>Risk Assessment<br/>Survival Analysis<br/>Taxoids--administration & dosage<br/>Treatment Outcome